IBDEI24Y ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,35839,1,4,0)
 ;;=4^O36.0115
 ;;^UTILITY(U,$J,358.3,35839,2)
 ;;=^5016847
 ;;^UTILITY(U,$J,358.3,35840,0)
 ;;=O36.0120^^166^1827^49
 ;;^UTILITY(U,$J,358.3,35840,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35840,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, second trimester, unsp
 ;;^UTILITY(U,$J,358.3,35840,1,4,0)
 ;;=4^O36.0120
 ;;^UTILITY(U,$J,358.3,35840,2)
 ;;=^5016849
 ;;^UTILITY(U,$J,358.3,35841,0)
 ;;=O36.0121^^166^1827^50
 ;;^UTILITY(U,$J,358.3,35841,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35841,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, second tri, fetus 1
 ;;^UTILITY(U,$J,358.3,35841,1,4,0)
 ;;=4^O36.0121
 ;;^UTILITY(U,$J,358.3,35841,2)
 ;;=^5016850
 ;;^UTILITY(U,$J,358.3,35842,0)
 ;;=O36.0122^^166^1827^51
 ;;^UTILITY(U,$J,358.3,35842,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35842,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, second tri, fetus 2
 ;;^UTILITY(U,$J,358.3,35842,1,4,0)
 ;;=4^O36.0122
 ;;^UTILITY(U,$J,358.3,35842,2)
 ;;=^5016851
 ;;^UTILITY(U,$J,358.3,35843,0)
 ;;=O36.0123^^166^1827^52
 ;;^UTILITY(U,$J,358.3,35843,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35843,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, second tri, fetus 3
 ;;^UTILITY(U,$J,358.3,35843,1,4,0)
 ;;=4^O36.0123
 ;;^UTILITY(U,$J,358.3,35843,2)
 ;;=^5016852
 ;;^UTILITY(U,$J,358.3,35844,0)
 ;;=O36.0124^^166^1827^53
 ;;^UTILITY(U,$J,358.3,35844,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35844,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, second tri, fetus 4
 ;;^UTILITY(U,$J,358.3,35844,1,4,0)
 ;;=4^O36.0124
 ;;^UTILITY(U,$J,358.3,35844,2)
 ;;=^5016853
 ;;^UTILITY(U,$J,358.3,35845,0)
 ;;=O36.0125^^166^1827^54
 ;;^UTILITY(U,$J,358.3,35845,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35845,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, second tri, fetus 5
 ;;^UTILITY(U,$J,358.3,35845,1,4,0)
 ;;=4^O36.0125
 ;;^UTILITY(U,$J,358.3,35845,2)
 ;;=^5016854
 ;;^UTILITY(U,$J,358.3,35846,0)
 ;;=O36.0130^^166^1827^55
 ;;^UTILITY(U,$J,358.3,35846,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35846,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, third trimester, unsp
 ;;^UTILITY(U,$J,358.3,35846,1,4,0)
 ;;=4^O36.0130
 ;;^UTILITY(U,$J,358.3,35846,2)
 ;;=^5016856
 ;;^UTILITY(U,$J,358.3,35847,0)
 ;;=O36.0131^^166^1827^56
 ;;^UTILITY(U,$J,358.3,35847,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35847,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, third tri, fetus 1
 ;;^UTILITY(U,$J,358.3,35847,1,4,0)
 ;;=4^O36.0131
 ;;^UTILITY(U,$J,358.3,35847,2)
 ;;=^5016857
 ;;^UTILITY(U,$J,358.3,35848,0)
 ;;=O36.0132^^166^1827^57
 ;;^UTILITY(U,$J,358.3,35848,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35848,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, third tri, fetus 2
 ;;^UTILITY(U,$J,358.3,35848,1,4,0)
 ;;=4^O36.0132
 ;;^UTILITY(U,$J,358.3,35848,2)
 ;;=^5016858
 ;;^UTILITY(U,$J,358.3,35849,0)
 ;;=O36.0133^^166^1827^58
 ;;^UTILITY(U,$J,358.3,35849,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35849,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, third tri, fetus 3
 ;;^UTILITY(U,$J,358.3,35849,1,4,0)
 ;;=4^O36.0133
 ;;^UTILITY(U,$J,358.3,35849,2)
 ;;=^5016859
 ;;^UTILITY(U,$J,358.3,35850,0)
 ;;=O36.0134^^166^1827^59
 ;;^UTILITY(U,$J,358.3,35850,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35850,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, third tri, fetus 4
 ;;^UTILITY(U,$J,358.3,35850,1,4,0)
 ;;=4^O36.0134
 ;;^UTILITY(U,$J,358.3,35850,2)
 ;;=^5016860
 ;;^UTILITY(U,$J,358.3,35851,0)
 ;;=O36.0135^^166^1827^60
 ;;^UTILITY(U,$J,358.3,35851,1,0)
 ;;=^358.31IA^4^2
